Biosimilars Breaching Borders: How FDA and EMA Find Common Ground
By HA Dowlat and Karl-Ludwig Rost Human clinical pharmacology pharmacokinetic (PK) and pharmacodynamic (PD) studies are vital for many reasons, and uniquely useful in extrapolating the efficacy and safety of biosimilars. PK and PD studies are the most objective clinical trials, and are sensitive to changes in a drug product. But the workings and concepts […]